The approval is based on results of the FELIX trial, which evaluated the safety and efficacy of obe-cel. The approval is based on results of the phase I/II AUGMENT-101 trial, where revumenib achieved a CR+CRh rate of 21%. The interest in using quantitative tests to measure residual cancer cells continues to expand in the arena of blood cancers. Since 1974, Dr. Steven Rosenberg has served as Chief of the Surgery Branch at the NCI. Dr. Lunning discusses his origins in clinical research, the rise of cellular therapy, and more. The IMS presented annual awards to three multiple myeloma clinicians and researchers during the 21st Annual Meeting. A retrospective study highlighted differences in infection rates and healthcare utilization following CAR-T therapy. Mezigdomide, tazemetostat, and dexamethasone demonstrated promising efficacy and safety in relapsed or refractory MM. A phase II trial in patients with at least three prior treatments evaluated two target doses of the CAR T-cell therapy. The agent is newly approved in polytherapy with bortezomib and dexamethasone for multiple myeloma in adults. The approval is based on results of the ASC4FIRST trial, which compared asciminib versus investigator-selected TKIs. The agent is a first-of-its-kind, orally available, selective inhibitor of the nuclear export protein exportin 1. Dr. Luskin describes why she pursued hematology-oncology, how she overcomes career challenges, and more. Dr. Scheinberg succeeds Guillermo Garcia-Manero, MD, as president of the Society of Hematologic Oncology. Ching-Hon Pui, MD, and John Seymour, MBBS, FRACP, PhD, were recognized for their contributions to blood cancer research. SOHO is teaming up with ABHH for a joint session at the 2024 HEMO meeting in São Paulo, Brazil October 23-26. While research on CHIP has gained momentum in recent years, treating the premalignant condition remains in debate. Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, reflects on life as an oncologist in 2024. The anti-CD19 autologous CAR-T-cell therapy was approved for use in adults with relapsed or refractory disease. The new indication for daratumumab and hyaluronidase-fihj plus D-VRd is based on results from the phase II CEPHEUS study.